These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 25371693)

  • 1. Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012.
    Rennie RP; Jones RN
    Can J Infect Dis Med Microbiol; 2014 Sep; 25(5):285-7. PubMed ID: 25371693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
    Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
    Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
    Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
    Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
    BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antimicrobial resistance monitoring of gram-negative bacilli isolated from 15 teaching hospitals in 2014 in China].
    Wang Q; Wang H; Yu Y; Xu X; Sun Z; Lu J; Yang B; Zhang L; Hu Z; Feng X; Xu Y; Ni Y; Mei Y; Liao K; Ji P; Chu Y
    Zhonghua Nei Ke Za Zhi; 2015 Oct; 54(10):837-45. PubMed ID: 26675021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?
    Cantón R; Canut A; Morosini MI; Oliver A
    Enferm Infecc Microbiol Clin; 2014 Dec; 32 Suppl 4():33-40. PubMed ID: 25542050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breakpoint beware: reliance on historical breakpoints for Enterobacteriaceae leads to discrepancies in interpretation of susceptibility testing for carbapenems and cephalosporins and gaps in detection of carbapenem-resistant organisms.
    Yarbrough ML; Wallace MA; Potter RF; D'Souza AW; Dantas G; Burnham CD
    Eur J Clin Microbiol Infect Dis; 2020 Jan; 39(1):187-195. PubMed ID: 31679102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints.
    Gupta V; Yu KC; Pogue JM; Watts JA; Clancy CJ
    Microbiol Spectr; 2022 Jun; 10(3):e0115822. PubMed ID: 35638777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting doripenem susceptibility based on meropenem and imipenem interpretation for Pseudomonas aeruginosa.
    Hagihara M; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2012 Mar; 72(3):258-62. PubMed ID: 22209563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
    Jean SS; Lee WS; Bai KJ; Yu KW; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    Diagn Microbiol Infect Dis; 2015 Apr; 81(4):290-5. PubMed ID: 25600841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative review of the carbapenems.
    Zhanel GG; Wiebe R; Dilay L; Thomson K; Rubinstein E; Hoban DJ; Noreddin AM; Karlowsky JA
    Drugs; 2007; 67(7):1027-52. PubMed ID: 17488146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Carbapenem resistance in ESBL positive Enterobacteriaceae isolates causing invasive infections].
    Eser OK; Altun Uludağ H; Ergin A; Boral B; Sener B; Hasçelik G
    Mikrobiyol Bul; 2014 Jan; 48(1):59-69. PubMed ID: 24506716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
    Jean SS; Lee WS; Yu KW; Liao CH; Hsu CW; Chang FY; Ko WC; Chen RJ; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Lam C; Liu CY; Hsueh PR
    J Microbiol Immunol Infect; 2016 Dec; 49(6):969-976. PubMed ID: 25661253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of adopting minimum inhibitory concentration as the determinant of susceptibility to cephalosporins and carbapenems in multi-drug resistant Enterobacteriaceae.
    Parta M
    Eur J Clin Microbiol Infect Dis; 2012 Jun; 31(6):975-80. PubMed ID: 21912922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbapenem-Resistant Enterobacteriaceae Detection Practices in California: What Are We Missing?
    Humphries RM; Hindler JA; Epson E; Horwich-Scholefield S; Miller LG; Mendez J; Martinez JB; Sinkowitz J; Sinkowtiz D; Hershey C; Marquez P; Bhaurla S; Moran M; Pandes L; Terashita D; McKinnell JA
    Clin Infect Dis; 2018 Mar; 66(7):1061-1067. PubMed ID: 29099915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints.
    Lazzerini G; Lavey SC; Fox BC; Munson E
    Clin Med Res; 2022 Jun; 20(2):81-88. PubMed ID: 35086853
    [No Abstract]   [Full Text] [Related]  

  • 17. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
    Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
    Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1313-9. PubMed ID: 15047535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: report of the 2001 data from 15 United States medical centres.
    Rhomberg PR; Jones RN; Sader HS;
    Int J Antimicrob Agents; 2004 Jan; 23(1):52-9. PubMed ID: 14732314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.